VanEck Video Gaming and eSports ETF vs Regeneron Pharmaceuticals Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $97.96, while Regeneron Pharmaceuticals Inc trades at $800.23 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while VanEck Video Gaming and eSports ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $812.27 |
52-Week Low | $85.25 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.98, down 1.63% today, with technical indicators showing a bullish bias as moving averages and oscillators signal buying opportunities. The stock shows strong momentum with ADX readings indicating a trending market. Support levels are established at $96, $97, and $98, while resistance sits at $100, $101, and $102.
The bullish technical setup suggests potential upside toward resistance levels, though fundamental analysis is limited due to unavailable financial ratios. Investors should monitor upcoming earnings reports for revenue growth and profitability metrics to validate the technical strength with fundamental support.
Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.
The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →